Alexander Crichton

671 posts

Alexander Crichton banner
Alexander Crichton

Alexander Crichton

@VascularABC

Vascular research fellow @Houston Methodist hospital, University of Birmingham PhD Student, OOPR West Midlands Vascular Resident, Father and Husband!

Houston, TX Katılım Aralık 2021
1.3K Takip Edilen621 Takipçiler
Alexander Crichton retweetledi
Alan Lumsden, MD, CV Chairman/Director
Dr Dora Zatyko discussing use of computer vision technologies to analyze work flows in 6 different hospitals. ⁦@apella_
Alan Lumsden, MD, CV Chairman/Director tweet media
English
0
2
8
540
Alexander Crichton retweetledi
Trisha L. Roy MD PhD FACS
Trisha L. Roy MD PhD FACS@trisharoymd·
Beautiful day in San Diego to kick off #SCVS2026. What does it take to go from being a vascular surgeon to being a chief? A chair? In the c-suite?
Trisha L. Roy MD PhD FACS tweet mediaTrisha L. Roy MD PhD FACS tweet mediaTrisha L. Roy MD PhD FACS tweet media
English
1
5
20
1.6K
Alexander Crichton retweetledi
evocc_trial
evocc_trial@Evocc_Trial·
Huge congratulations to Royal Stoke, York and Leicester on their recent randomisations for EVOCC. We are now just 2 participants away from reaching 50% of the trial recruitment target! 🙌🥳 @LeicesterCTU @a_saratzis
English
1
3
4
279
Alexander Crichton retweetledi
Arindam Chaudhuri
Arindam Chaudhuri@vascularis·
@trisharoymd A dynamic vascular scientist who is pushing the boundaries in her field with a great team! @VascularABC
EJVES@EJVES_ESVS

🌟 AUTHOR SPOTLIGHT: Dr. Trisha Roy 🌟 Visualizing the invisible: How drugs interact with complex plaque. In a recent #EJVESForum study, @TrishaRoyMD and her team at Houston Methodist and Weill Cornell Medical College developed a groundbreaking Scanning Electron Microscopy (SEM) approach to evaluate how paclitaxel is deposited from Drug-Coated Balloons (DCBs). 🔍 MEET THE AUTHOR: Affiliations: Houston Methodist Hospital & Weill Cornell Medical College, Houston, TX, USA 🇺🇸. Expertise: A pioneer in using advanced imaging and human cadaveric models to study peripheral artery disease (PAD) and endovascular outcomes. The Vision: Moving beyond animal models to understand how vessel preparation—like cutting balloons—changes drug transfer in real human calcified lesions. 💡 WHY THIS RESEARCH MATTERS: Current DCB data often comes from healthy animal vessels, which don't mimic the "rock-hard" calcium surgeons face daily. Dr. Roy’s work uses a human cadaveric PAD model to show that vessel preparation significantly impacts how much drug actually stays on the vessel wall. 🚀 THE CLINICAL IMPACT: By using SEM to map drug distribution at a microscopic level, we can finally see why some lesions respond to DCBs while others don't. It’s about optimizing every millimeter of the artery for the best long-term patency. Read the full study and join the discussion 👇 ejvesvascularforum.com/article/S2666-… #EJVESforum #VascTwitter #VascularSurgery #PAD #DCB #ScanningElectronMicroscopy #MedEd #ESVScommunity #VasculaRes #SurgicalInnovation #MeetTheAuthor @vascularis @bazinger_z @FLareyre @MariaKatsarou14 @NicLeoneMD @ESVSmembership @EVST_ESVS @WeillCornell @HMethodistCV @HMethodistMD @MethodistHosp

English
0
2
6
468
Alexander Crichton retweetledi
Trisha L. Roy MD PhD FACS
Trisha L. Roy MD PhD FACS@trisharoymd·
When using DCBs, how much drug actually gets to the vessel wall? Plaque morphology matters and SEM can show us. Time to personalize our treatment strategies to the patients lesions and not rely on “one size fits all” for PAD! @AlanLumsdenMD @DeBakeyCVedu
EJVES@EJVES_ESVS

🌟 AUTHOR SPOTLIGHT: Dr. Trisha Roy 🌟 Visualizing the invisible: How drugs interact with complex plaque. In a recent #EJVESForum study, @TrishaRoyMD and her team at Houston Methodist and Weill Cornell Medical College developed a groundbreaking Scanning Electron Microscopy (SEM) approach to evaluate how paclitaxel is deposited from Drug-Coated Balloons (DCBs). 🔍 MEET THE AUTHOR: Affiliations: Houston Methodist Hospital & Weill Cornell Medical College, Houston, TX, USA 🇺🇸. Expertise: A pioneer in using advanced imaging and human cadaveric models to study peripheral artery disease (PAD) and endovascular outcomes. The Vision: Moving beyond animal models to understand how vessel preparation—like cutting balloons—changes drug transfer in real human calcified lesions. 💡 WHY THIS RESEARCH MATTERS: Current DCB data often comes from healthy animal vessels, which don't mimic the "rock-hard" calcium surgeons face daily. Dr. Roy’s work uses a human cadaveric PAD model to show that vessel preparation significantly impacts how much drug actually stays on the vessel wall. 🚀 THE CLINICAL IMPACT: By using SEM to map drug distribution at a microscopic level, we can finally see why some lesions respond to DCBs while others don't. It’s about optimizing every millimeter of the artery for the best long-term patency. Read the full study and join the discussion 👇 ejvesvascularforum.com/article/S2666-… #EJVESforum #VascTwitter #VascularSurgery #PAD #DCB #ScanningElectronMicroscopy #MedEd #ESVScommunity #VasculaRes #SurgicalInnovation #MeetTheAuthor @vascularis @bazinger_z @FLareyre @MariaKatsarou14 @NicLeoneMD @ESVSmembership @EVST_ESVS @WeillCornell @HMethodistCV @HMethodistMD @MethodistHosp

English
1
2
12
2.1K
Alexander Crichton retweetledi
Trisha L. Roy MD PhD FACS
Trisha L. Roy MD PhD FACS@trisharoymd·
Huge congrats to Eniko Pomozi for winning First Prize #AVF2026 @VenousForum! Proud of our lab @HMethodistCV where we combine MRI, histo, human thrombus to understand clot biology and treatment. Amazing work by Eniko + team. Check us out at European Venous Forum in June!
Trisha L. Roy MD PhD FACS tweet mediaTrisha L. Roy MD PhD FACS tweet mediaTrisha L. Roy MD PhD FACS tweet media
English
0
4
23
1.4K
Alexander Crichton
Alexander Crichton@VascularABC·
should be illegal for managers to sub defenders on 59min currently holding a clean sheet ie preventing the 2 points for 60min plus the clean sheet points @ManCity 🤣 Don't they know the world revolves around my @OfficialFPL score @BBCSport says subbed at 60min #gimmedapoints 🤣
Alexander Crichton tweet media
English
0
0
3
73
Alexander Crichton retweetledi
Trisha L. Roy MD PhD FACS
Trisha L. Roy MD PhD FACS@trisharoymd·
Congratulations to our post doc Eniko! Highlighted in the #VEITH bulletin. Pushing PAD beyond anatomy toward biology-guided diagnosis is exactly the paradigm shift the field needs. HiPath is a powerful vision for what’s next. @AlanLumsden @HMethodistCV @DeBakeyCVedu
Trisha L. Roy MD PhD FACS tweet media
English
0
2
8
547
Alexander Crichton retweetledi
Trisha L. Roy MD PhD FACS
Trisha L. Roy MD PhD FACS@trisharoymd·
Big day at HMH PVD Device Core with the TCAT team (MicroVention/@Terumo), we tested next-gen BTK devices on real CLTI pathology: donated limbs, phenotyped with MRI + OCT. The future is informed design: the right device, right patient, first time, every time. @AlanLumsdenMD
Trisha L. Roy MD PhD FACS tweet mediaTrisha L. Roy MD PhD FACS tweet mediaTrisha L. Roy MD PhD FACS tweet media
English
0
4
17
1.7K
Alexander Crichton retweetledi
EJVES
EJVES@EJVES_ESVS·
🌍 🎯 QUERY: What is the True Foundation of Vascular Progress? 💥 Celebrating our Rising Impact Factor, our 2025 Reviewers, and the Future of #EJVESForum Happy New Year! As we begin 2026, we pause to reflect on a landmark year. Science is more than just data; it is a community—a family—built on the dedication of those who came before us and the tireless work of those currently behind the scenes. 💡 2025: A YEAR OF SERVICE & GROWTH Inspired by the collaborative spirit of the global vascular community, we want to celebrate the pillars of our journal: · Rising Impact: Since receiving our first Impact Factor in 2023, we have seen remarkable growth, with our Impact Factor rising to 1.8 in 2025! This climb reflects the increasing relevance of the clinical insights shared by our authors. · Reviewers & Commentaries: Success would be impossible without our reviewers. Beyond ensuring quality, your Reviewer Commentaries are essential to the journal's mission, providing the context and "expert take" that deepen the community's understanding of every paper. · The Authors: Thank you for your trust in sharing your research and clinical "lessons learned" with us throughout 2025. · The Editorial Team: Recognition to our associate editors and production staff, whose meticulous work ensures the highest standards in every publication. 🚀 2026: INNOVATION & FUTURE PERSPECTIVES This year, we are taking important steps to bring high-quality science to an even broader audience: · Digital Transformation: We are enhancing our integration of videos and multimedia to enrich clinical discussion and bring surgical techniques to life. · Expanding Global Reach: With our rising IF, we are focused on even broader indexing to ensure your work has the visibility it deserves. · Reviewer Mentorship: Launching initiatives to support the next generation of experts in developing their peer-review and commentary skills. 👉 TAKEAWAY: A Legacy in Every Review Every contribution strengthens the advancement of vascular surgery. We honour the legacy of the greats who inspired us by carrying forward their commitment to ethical standards and collaborative spirit into this new year. Thank you for being an essential part of our journey. Let's make 2026 our best year yet! #EJVESforum #ImpactFactor #VascularSurgery #PeerReview #AcademicPublishing #MedEd #ESVScommunity #VasculaRes #SurgicalEducation #ScientificIntegrity #NewYear2026 @vascularis @bazinger_z @FLareyre @maria_katsarou_ @NicLeoneMD @ESVSmembership @EVST_ESVS
EJVES tweet mediaEJVES tweet mediaEJVES tweet media
English
2
14
17
1.7K